Sonidegib: all 40 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingNCT05669339Phase 2
• Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell CarcinomaTerminatedNCT02303041Phase 2Results posted
• Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
• A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate CancerCompletedNCT02111187Phase 1Results posted
• Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02086552Phase 2Results posted
• Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) PatientsCompletedNCT02027376Phase 1Results posted
• LDE225 for Patients With PTCH1 or SMO Mutated TumorsTerminatedNCT02002689Phase 2Results posted
• Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute LeukemiaCompletedNCT01826214Phase 2Results posted
• A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFCompletedNCT01787552Phase 1/2Results posted
• A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)CompletedNCT01708174Phase 2Results posted
• Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened InhibitorsCompletedNCT01529450Not applicableResults posted
• Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic AdenocarcinomaTerminatedNCT01431794Phase 1/2Results posted
• Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)CompletedNCT01350115Phase 2Results posted
• A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaCompletedNCT01327053Phase 2Results posted
• A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MBCompletedNCT01125800Phase 1/2Results posted
• To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)TerminatedNCT01033019Phase 2Results posted
• Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in ChinaCompletedNCT06880848Phase 4
• Tailored Sonidegib Schedule After Complete Response in BCCActive, not recruitingNCT04806646Phase 2
• Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed MedulloblastomaTerminatedNCT04402073Phase 2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain TumorsCompletedNCT03434262Phase 1
• Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian CancerCompletedNCT02195973Phase 1
• LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After DocetaxelWithdrawnNCT02182622Phase 1
• LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 CirrhosisCompletedNCT02151864Phase 1
• LDE225 + Everolimus in Advanced Gastroesophageal AdenocarcinomaCompletedNCT02138929Phase 1
• Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
• Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCTTerminatedNCT02086513Phase 1
• LDE225 and Paclitaxel in Solid TumorsCompletedNCT01954355Phase 1
• A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic CancerWithdrawnNCT01911416Not applicable
• Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in PatientsCompletedNCT01769768Phase 1
• Effect of Hepatic Impairment on LDE225..CompletedNCT01764776Phase 1
• LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast CancerWithdrawnNCT01757327Phase 2
• A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas CancerWithdrawnNCT01694589Early Phase 1
• Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)CompletedNCT01579929Phase 1
• Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsCompletedNCT01576666Phase 1
• Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer PatientsCompletedNCT01487785Phase 1
• LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic CancerCompletedNCT01485744Phase 1
• Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior TherapyCompletedNCT01456676Phase 1
• An East Asian Study of LDE225CompletedNCT01208831Phase 1
• Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid TumorsCompletedNCT00880308Phase 1

← Sonidegib overview